VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ORKA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ORKAOruka Therapeutics, Inc.
$96.32$5.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksORKABalance Sheet

Oruka Therapeutics, Inc. (ORKA) Balance Sheet

21Y historyFree accessUpdated daily

Total debt of only $2.9M against $1.2B in equity yields a near-zero debt-to-equity ratio, though the balance sheet appears vulnerable given cash of $191.5M against a $44.3M quarterly operating outflow and a -$312.1M accumulated deficit.

Income StatementBalance SheetCash FlowRatios

ORKA Balance Sheet

Annual statement

ORKA Balance Sheet

Oruka Therapeutics, Inc. (ORKA) balance sheet — 21-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05
Total Current Assets941.49M343.86M376.87M37.59M42.7M54.42M49.97M8.48M6.78M12.3M21.45M38.92M15.49M16.93M3.04M6.21M7.16M8.29M9.68M99.99M166.34M85.77M
Cash & Short-Term Investments920.28M337.04M375.65M37.43M42.45M53.36M49.07M8.36M6.61M11.75M21.16M38.8M15.35M16.76M2.92M5.94M7.03M7.76M7.74M97.57M153.13M70.34M
Cash Only191.52M46.94M61.58M37.43M42.45M53.36M49.07M8.36M6.61M8.7M7.4M38.8M15.35M16.76M2.92M5.94M7.03M7.76M7.74M32.06M60.34M37.76M
Short-Term Investments728.76M290.11M314.07M0000003.05M13.76M0000000065.51M92.79M32.57M
Accounts Receivable0000000000000000000588K8.56M1.21M
Days Sales Outstanding-------------------4.58803.51808.36
Inventory0000000000000000000000
Days Inventory Outstanding----------------------
Other Current Assets06.81M1.22M161K254K1.06M897K117K169K547K282K114K134K169K125K269K137K522K1.94M1.83M4.65M1.96M
Total Non-Current Assets289.53M144.76M19.15M269K386K503K461K56K48K66K3.18M658K644K159K167K290K994K1.09M1.4M20.7M18.07M22.28M
Property, Plant & Equipment3.1M2.12M1.04M257K368K485K449K32K24K42K66K28K36K29K23K66K690K1.03M1.3M8.91M11.98M15.16M
Fixed Asset Turnover0.00x------------------5.26x0.32x0.04x
Goodwill00000000000000000004.67M4.67M4.67M
Intangible Assets0000000000000000000000
Long-Term Investments787.99M142.54M18.07M00000002.35M000000006M00
Other Non-Current Assets128K103K43K12K18K18K12K24K24K24K766K630K608K130K144K224K304K61K98K1.12M1.42M2.44M
Total Assets1.23B488.62M396.02M37.86M43.09M54.92M50.43M8.54M6.83M12.37M24.63M39.57M16.13M17.08M3.21M6.5M8.16M9.37M11.08M120.68M184.41M108.05M
Asset Turnover0.00x------------------0.39x0.02x0.01x
Asset Growth %417.67%23.38%945.98%-12.12%-21.56%8.91%490.78%25.07%-44.8%-49.8%-37.76%145.31%-5.57%431.88%-50.6%-20.28%-12.97%-15.41%-90.82%-34.56%70.67%-
Total Current Liabilities31.78M15.37M13.04M637K1.13M3.5M3.5M926K793K2.07M2.4M1.5M1.39M1.5M305K754K1.19M1.64M15.83M18.19M43.84M36.18M
Accounts Payable14.38M4.16M3.46M0334K1.12M1.77M418K230K622K000597K65K260K388K533K804K2.76M7.03M4.92M
Days Payables Outstanding16.88K18.27K46.8K-1.07K4.48K6.96K1.71K3.82K8.41K---8.38K551.7432.53418.99--429.96805.9431.07
Short-Term Debt0619K213K76K103K100K41K25K000000000012.3M03.66M8.29M
Deferred Revenue (Current)0000000000000016K33K000000
Other Current Liabilities50K5.33M7.33M461K522K1.36M870K354K413K691K1.68M835K1.06M446K121K350K627K870K1.66M13.08M30.06M20.7M
Current Ratio29.62x22.37x28.89x59.01x37.72x15.56x14.28x9.16x8.55x5.94x8.95x25.88x11.16x11.27x9.98x8.24x6.02x5.04x0.61x5.50x3.79x2.37x
Quick Ratio29.62x22.37x28.89x59.01x37.72x15.56x14.28x9.16x8.55x5.94x8.95x25.88x11.16x11.27x9.98x8.24x6.02x5.04x0.61x5.50x3.79x2.37x
Cash Conversion Cycle----------------------
Total Non-Current Liabilities2.09M1.31M755K204K280K383K409K0020K39K03K1K016K195K316K562K34.84M70.72M15.1M
Long-Term Debt0000000000000000000019.07M3.78M
Capital Lease Obligations6.41M1.31M755K204K280K383K409K000000000000000
Deferred Tax Liabilities0000000000000000000000
Other Non-Current Liabilities00000000020K39K0000000132K13.18M125K359K
Total Liabilities33.88M16.69M13.8M841K1.41M3.88M3.91M926K793K2.09M2.44M1.5M1.39M1.5M305K770K1.39M1.96M16.39M53.02M114.56M51.28M
Total Debt2.93M1.93M968K280K383K483K450K25K000000000012.3M022.73M12.07M
Net Debt-188.59M-45M-60.61M-37.15M-42.06M-52.88M-48.62M-8.34M-6.61M-8.7M-7.4M-38.8M-15.35M-16.76M-2.92M-5.94M-7.03M-7.76M4.56M-32.06M-37.61M-25.69M
Debt / Equity0.00x0.00x0.00x0.01x0.01x0.01x0.01x0.00x------------0.33x0.21x
Debt / EBITDA-0.02x---------------------
Net Debt / EBITDA1.03x---------------------
Interest Coverage---56.03x----1082.00x-806.00x-------1439.00x-1071.80x-1051.50x-60.72x-108.16x-118.43x-224.81x-70.05x
Total Equity1.2B471.93M382.22M37.02M41.67M51.04M46.52M7.61M6.03M10.28M22.19M38.07M14.74M15.58M2.91M5.73M6.77M7.41M-5.31M67.66M69.84M56.76M
Equity Growth %427.18%23.47%932.47%-11.17%-18.36%9.72%511.31%26.16%-41.29%-53.7%-41.7%158.26%-5.39%435.98%-49.28%-15.34%-8.65%239.51%-107.85%-3.13%23.04%-
Book Value per Share16.7210.3522.772.572.893.679.8869.1294.08212.76528.711307.481087.172730.161977.555182.647221.289480.92-999999.00230177.36246298.69249503.62
Total Shareholders' Equity1.2B471.93M382.22M37.02M41.67M51.04M46.52M7.61M6.03M10.28M22.19M38.07M14.74M15.58M2.91M5.73M6.77M7.41M-5.31M67.66M69.84M56.76M
Common Stock67K49K37K14K14K14K10K2K14K12K9K9K21K16K3K12K9K8K1K53K53K44K
Retained Earnings-312.15M-189.16M-83.72M-188.74M-183.4M-173.48M-154.15M-144.42M-138.93M-131M-112.51M-96.07M-84.62M-74.93M-67.99M-63.67M-58.31M-49.89M-40.75M-470.51M-458.21M-327.66M
Treasury Stock0000000000000000000000
Accumulated OCI-5.04M546K-41K000000-2K-19K0000000049K10K-250K
Minority Interest0000000000000000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Dilutive financing dependence risk

Balance Sheet Expands Through Equity Raises

According to recent SEC filings, ORKA's total assets rose from roughly $33.8M in 2024Q2 to $1.2B in 2026Q3, a pattern driven almost entirely by equity capital rather than operating earnings, which carry no contribution given the company's pre-revenue status.

The equity base has grown from $32.6M to about $1.2B while retained earnings deepened from -$193.4M to -$312.1M, which suggests the expansion reflects capital injections rather than accumulated profitability. Investors should view the rapid asset growth as a function of financing activity, and the magnitude of the 2026Q2 jump warrants further investigation into the terms and dilution associated with those raises.

Cash Buffer Thin Against Quarterly Burn

Based on reported figures, ORKA held approximately $46.9M in cash at 2025Q4 and $191.5M at 2026Q3, against a latest quarterly operating cash outflow of roughly $44.3M, leaving the buffer sensitive to the timing of subsequent financing.

The current ratio of 29.62 in 2026Q3 appears strong on its face, but it reflects a near-zero liability base rather than abundant operating resilience. Measured against the most recent quarterly burn, the reported cash position suggests only a few quarters of runway, which may indicate that the company's ability to reach its next clinical readout depends on continued access to capital markets.

Negligible Debt Keeps Leverage Minimal

As reported in financial statements, ORKA's total debt stood at $2.9M in 2026Q3 against $1.2B in equity, producing a debt-to-equity ratio near zero and placing leverage risk well outside the company's current capital structure concerns.

The minimal debt load means refinancing risk is effectively data unavailable as a meaningful pressure point at present. The more relevant balance sheet exposure is the reliance on equity financing, which may dilute existing holders as the company funds clinical spend rather than borrowing against future cash flows.

Asset-Light Profile Concentrates in Cash

Based on reported figures, ORKA's PPE net stood at only $3.1M in 2026Q3 and goodwill was recorded at zero, indicating that nearly all reported assets consist of cash and short-term holdings rather than productive physical infrastructure.

This asset mix is consistent with an outsourced clinical-stage model in which manufacturing and discovery are handled externally, reducing fixed capital requirements. The absence of goodwill removes impairment risk from the balance sheet, though the lack of tangible operating assets means value rests almost entirely on the clinical pipeline rather than on hard collateral.

Accumulated Deficit Widens Despite Equity Growth

According to recent SEC filings, ORKA's retained earnings deficit widened from -$193.4M in 2024Q2 to -$312.1M in 2026Q3, even as paid-in capital expanded substantially, indicating that equity raises have been absorbed by operating losses.

Stock-based compensation of $9.1M in 2026Q3 contributes to the equity base through non-cash charges, which may partially inflate the apparent book value relative to cash generated. Shareholders should monitor how the continued issuance of shares to fund clinical programs affects per-share value, as the deficit trend suggests dilution is a recurring feature of the capital structure.

Asset Growth Masks Shrinking Runway

Based on reported figures, the headline $1.2B asset base in 2026Q3 may overstate near-term financial flexibility, since reported cash of $191.5M compares against a quarterly operating outflow near $44.3M and the cumulative burn across ten quarters exceeds $260M.

The gap between total assets and cash suggests much of the reported balance sheet value may not be readily available to fund operations, which warrants monitoring of the composition of non-cash assets. Investors should be cautious about interpreting the headline equity figure as evidence of durable capital strength, since the company's cash-based runway appears materially shorter than the asset total implies.

ORKA — Frequently Asked Questions

Quick answers to the most common questions about buying ORKA stock.

What are the total assets of Oruka Therapeutics, Inc. (ORKA)?

As of 2025, Oruka Therapeutics, Inc. (ORKA) had total assets of $488.6M including $343.9M in current assets.

How much debt does Oruka Therapeutics, Inc. (ORKA) have?

Oruka Therapeutics, Inc. (ORKA) carries total debt of $1.9M, offset by $337.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Oruka Therapeutics, Inc.?

Oruka Therapeutics, Inc. (ORKA) has total shareholders' equity (book value) of $471.9M ($10.35 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Oruka Therapeutics, Inc.'s current ratio and liquidity?

Oruka Therapeutics, Inc. (ORKA) reported a current ratio of 22.37x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.